Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estimulación no invasiva del nervio mediano para atenuar las taquiarritmias auriculares después de la ablación con catéter para la fibrilación auricular (NEUROPULSE)

6 de noviembre de 2026 actualizado por: Vivek Reddy, Icahn School of Medicine at Mount Sinai

Determine the role of vagal/median nerve stimulation using the CardiaCare RR2 home care wearable neuromodulation system on suppressing atrial arrhythmias and related symptoms in patients who have undergone AF ablation. The study population will be comprised of adults (age ≥18 yrs.) who have undergone AF ablation for paroxysmal or persistent AF.

The study will assess the ability of neuromodulation, using the CardiaCare RR2 home care wearable, to suppress the following:

  1. early (0-2 months) post-ablation arrhythmias that occur in the immediate post-ablation time period
  2. AF/AT/AFL recurrences between months 2-6 post-ablation.This is a prospective, controlled, double-blind, randomized trial. The first 15 patients will not be randomized and will receive the active median/vagal stimulation only (open label).

The Study will be conducted in up to 1 clinical site in the United States. This study will have 1:1 randomization (active median/vagal stimulation vs sham). The study has been given NSR designation from FDA--NO IDE.

Descripción general del estudio

Estado

Terminado

Descripción detallada

Study will include continuous ECG assessment at 2 (0 for the first 15 patients, open label), 6 and 22 weeks from enrollment for 2 weeks (for 4 weeks at the first measurement for the first 15 patients, open label) and at least daily single lead ECG assessments throughout the follow up period. The ECG's generated can be viewed by physicians only to assess the frequency of RR2 treatments and will not be used to alter any other aspects of standard of care, including medical management, which will continue according to standard of care throughout the study. Patients and investigators will be blinded during the trial. Patients with paroxysmal or persistent AF undergoing AF ablation will be recruited post ablation procedure during hospitalization. During screening/baseline visit, eligible patients will be randomized to either an active treatment or a sham group (1:1 accordingly). The first 15 eligible patients will not be randomized and will receive the active median/vagal stimulation only (open label).

Patients will receive training on the RR2 for home-care use, by study personnel either in person or via a video conference meeting. An instructional video will also be available for users. Patients will be ordered to measure at home, 2 min ECG measurements with the RR2 system, two times a day throughout the study and when feeling symptoms suspected related to AF (AF/AT/PAC).

In addition, Patients will be instructed to perform Neuromodulation sessions with the RR2 home care device. Once a day for the first 2 weeks followed by three times per week for the remaining duration of the study. Additional treatments, up to once daily, will be added during this period in case the patient feels symptom, verified on single lead ECG and site staff.

Treatments will be conducted for a period of 6 months. During the study, the patients will continue to take Standard of care medication. Medications will be recorded throughout the study.

Patient Diary will be dispensed and or APP diary questioners will be used by the subject in order to document symptoms suspected as related to arrhythmia events.

Tipo de estudio

Intervencionista

Inscripción (Actual)

51

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • New York
      • New York, New York, Estados Unidos, 10029
        • Icahn School of Medicine at Mount Sinai

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria

  • Men and women ages ≥18 years
  • Patients planned to undergo or undergoing AF ablation for paroxysmal or persistent AF and able to be randomized within 48 hours of the ablation procedure.
  • Ability and willingness to sign an informed consent form.
  • Ability and willingness to use CardiaCare RR2 device, continuous ECG monitoring, and has an available SmartPhone.

Exclusion Criteria

  • Rheumatic heart disease
  • Extensive atrial disease (* some patients may be determined to be screen failures following the ablation procedure).
  • Moderate to severe mitral stenosis or history of mitral valve replacement
  • Pacemaker or CRTD or any implanted electrical stimulating device
  • Unilateral or bilateral vagotomy
  • Peripheral neuropathy affecting the tested upper extremity.
  • Severe heart failure (New York Heart Association Class III or IV) within 90 days.
  • Recent (within 90 days) stroke or transient ischemic attack.
  • Recent (within 90 days) myocardial infarction.
  • Pregnancy or breast feeding.
  • Life expectancy <1 year for any medical condition
  • Currently enrolled in another study that would interfere with this study
  • Unsuitable for participating in the study according to attending physician

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Participants with CardiaCare RR2

Participants undergoing Neuromodulation Sessions (mNVS) and Active Median/Vagal Stimulation. Patients will receive training on the RR2 for home-care use, by study personnel either in person or via a video conference meeting. An instructional video will also be available for users.

CardiaCare has developed a wrist band that delivers non-invasive neuromodulation to the median nerve to elicit a vagal response (Median-Vagus nerve stimulation-mVNS). The device is in the post-prototype development stage and is ready for human clinical trials. The CardiaCare RR2 device has already been approved by the IRB of the Chaim Sheba Medical Center, IL and the IL MOH (Ministry of Health) in an already completed pilot clinical trial for modulating AF.

Comparador falso: Participants with Sham Device

Sham device will be dispensed, which will create a sensation but not provide therapy

Sham device will be dispensed, which will create a sensation but not provide therapy

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
AF/AFL occurrence
Periodo de tiempo: at 2-months and 6-months post-ablation procedure

Burden of AF/AFL (defines as 30 seconds or longer) during the 2-months and 6-months period after ablation measured using ECG-patch monitoring and daily RR2 single lead ECG.

at 2-months and 6-months post-ablation procedure

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Número de visitas a urgencias
Periodo de tiempo: 6 meses post-ablación
6 meses post-ablación
Número de hospitalizaciones
Periodo de tiempo: 6 meses post-ablación
6 meses post-ablación
Número de cardioversiones
Periodo de tiempo: 6 meses post-ablación
6 meses post-ablación
Número de repeticiones de ablación
Periodo de tiempo: 6 meses post-ablación
6 meses post-ablación
Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence
Periodo de tiempo: 2-month and 6-month post-ablation procedure

Time to first AT or AF recurrence measured by CardiaCare RR2

2-month and 6-month post-ablation procedure
Number of arrythmia occurrences
Periodo de tiempo: 2-month and 6-month post-ablation procedure

Burden of all arrythmias between 2- and 6-months period after ablation will be measured using 2 weeks ECG-patch monitoring and daily RR2 single lead ECG.

2-month and 6-month post-ablation procedure
Number of Atrial Arrythmia Symptoms
Periodo de tiempo: 6-month post-ablation procedure

Difference in Atrial Arrythmia Symptoms during the 6 months period after ablation.

6-month post-ablation procedure
Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence
Periodo de tiempo: 6 months post-ablation

Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence during the 6-months period after ablation.

6 months post-ablation
Quality of Life measured using The European Heart Rhythm Association (EHRA) score
Periodo de tiempo: Baseline, 2-months, and 6-months

The investigators will assess the change in EHRA symptom scale. The EHRA score ranges from 1 to 4. Higher scores indicate more severe symptoms.

Baseline, 2-months, and 6-months
Quality of Life measured using Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Score
Periodo de tiempo: Baseline, 2-months, and 6-months

The AFEQT is a questionnaire assessing quality of life and symptoms in atrial fibrillation patients. It covers four subscales: patient symptoms, daily activities, treatment concerns, and treatment satisfaction. Subscales from 0-100, with Full Scale range from 0 to 100, with higher scores indicating better quality of life and fewer symptom burdens.

Baseline, 2-months, and 6-months
Change in PAC/AT/AFL before and after treatment with RR2
Periodo de tiempo: Baseline and 6-month post-ablation

Change, such as increase or decrease, in incidence/frequency of atrial arrhythmias before and after treatment with study device.

Baseline and 6-month post-ablation
Change in Heart Rate Variability (HRV)
Periodo de tiempo: Baseline and 6-month post-ablation

Heart rate variability (HRV) is the variation in the time interval between consecutive heartbeats. Higher HRV indicates better cardiovascular function and stress resilience.

Baseline and 6-month post-ablation

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Colaboradores

Investigadores

  • Investigador principal: Vivek Reddy, MD, Icahn School of Medicine at Mount Sinai
  • Investigador principal: Mohit Turagam, MD, Icahn School of Medicine at MS

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

2 de octubre de 2024

Finalización primaria (Actual)

30 de julio de 2026

Finalización del estudio (Actual)

30 de julio de 2026

Fechas de registro del estudio

Enviado por primera vez

19 de diciembre de 2024

Primero enviado que cumplió con los criterios de control de calidad

19 de diciembre de 2024

Publicado por primera vez (Actual)

27 de diciembre de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir